Hosted on MSN6d
Ionis and Sobi agree on olezarsen commercialisation
Ionis Pharmaceuticals has entered a licence agreement with Sobi in which the latter obtains exclusive rights to commercialise ...
Ionis Pharmaceuticals enters exclusive olezarsen license agreement with Sobi
Ionis Pharmaceuticals (IONS) announced that it has entered into a license agreement under which Sobi received exclusive rights in countries ...
pharmaphorum6d
FDA clears Ionis drug as first therapy for rare disease FCS
Ionis Pharma's olezarsen has become the first FDA-approved drug therapy for adults with familial chylomicronaemia syndrome (FCS), an ultra-rare disease that leads to elevated triglyceride levels ...
Yahoo Finance8d
Ionis expands partnership with Sobi to include olezarsen commercialization outside the U.S.
Ionis will continue to independently commercialize olezarsen in the U.S. Olezarsen was approved by the FDA in December 2024 under the tradename TRYNGOLZA™ as an adjunct to diet to reduce ...
Arrowhead Pharmaceuticals Is Finally Arriving
Arrowhead Pharmaceuticals, Inc. shines with 19 clinical programs, strategic partnerships, and promising RNAi data. Click for ...
pharmaphorum1y
Ionis preps filings for olezarsen in rare disease FCS
Ionis Pharma is preparing to file for regulatory approval of its experimental therapy olezarsen for familial chylomicronaemia syndrome (FCS) in the US and Europe after the drug met its targets in ...
Morningstar8d
Ionis expands partnership with Sobi to include olezarsen commercialization outside the U.S.
Ionis will continue to independently commercialize TRYNGOLZA™ (olezarsen) in the U.S. – Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that it has entered into a license agreement ...
Seeking Alpha8d
Ionis expands partnership with Sobi to include olezarsen commercialization outside the U.S.
Ionis Pharmaceuticals (NASDAQ:IONS) has entered into a license agreement under which Sobi receives exclusive rights in countries outside the U.S., Canada and China to commercialize olezarsen as a ...
Ionis expands partnership with Sobi to include olezarsen commercialization outside the U.S.
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that it has entered into a license agreement under which Sobi® ...